alfuzosin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihypertensive substances, prazosin derivatives	115	81403-80-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: alfuzosin alfuzosin hydrochloride xatral SL 77 alfuzosin HCl	Alfuzosin is a selective antagonist of post-synaptic alpha1-adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. Molecular weight: 389.46 Formula: C19H27N5O4 CLOGP: 2.35 LIPINSKI: 0 HAC: 9 HDO: 2 TPSA: 111.83 ALOGS: -3.14 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

alfuzosin
alfuzosin hydrochloride
xatral
SL 77
alfuzosin HCl

Alfuzosin is a selective antagonist of post-synaptic alpha1-adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.

Molecular weight: 389.46
Formula: C19H27N5O4
CLOGP: 2.35
LIPINSKI: 0
HAC: 9
HDO: 2
TPSA: 111.83
ALOGS: -3.14
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
7.50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	11 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.34 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	55 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.14 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 12, 2003	FDA	COVIS PHARMA SARL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Apraxia	66.35	41.63	13	947	1532	50602632
Dementia	60.09	41.63	19	941	15978	50588186
Disorientation	52.14	41.63	21	939	35463	50568701
Perseveration	51.08	41.63	8	952	255	50603909

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug dispensed to wrong patient	142.99	13.51	33	17208	242	29557044
Acute kidney injury	119.61	13.51	382	16859	264885	29292401
Orthostatic hypotension	90.46	13.51	87	17154	22542	29534744
Syncope	81.11	13.51	159	17082	81212	29476074
Fall	76.69	13.51	252	16989	176926	29380360
Antimicrobial susceptibility test resistant	66.70	13.51	18	17223	264	29557022
Confusional state	66.51	13.51	194	17047	127683	29429603
Wrong patient received product	64.83	13.51	30	17211	2252	29555034
Cholestasis	64.72	13.51	74	17167	23388	29533898
Hepatocellular injury	63.73	13.51	70	17171	21173	29536113
Agranulocytosis	57.53	13.51	65	17176	20275	29537011
Therapeutic response delayed	54.11	13.51	17	17224	435	29556851
Toxicity to various agents	50.65	13.51	19	17222	173642	29383644
Thrombocytopenia	49.73	13.51	182	17059	134641	29422645
Hypotension	47.98	13.51	232	17009	194122	29363164
Urinary retention	46.89	13.51	74	17167	31824	29525462
Eosinophilia	43.59	13.51	59	17182	22102	29535184
Coma	40.35	13.51	78	17163	39372	29517914
Staring	38.77	13.51	18	17223	1361	29555925
Pemphigoid	37.79	13.51	33	17208	7548	29549738
Drug interaction	37.32	13.51	219	17022	197166	29360120
Allergy to animal	36.29	13.51	11	17230	249	29557037
Disorganised speech	36.24	13.51	14	17227	669	29556617
Product storage error	33.94	13.51	29	17212	6441	29550845
Cell death	32.07	13.51	18	17223	2026	29555260
Completed suicide	31.55	13.51	7	17234	90239	29467047
Daydreaming	29.63	13.51	11	17230	471	29556815
Brain stem haematoma	29.48	13.51	8	17233	120	29557166
Wrong product administered	29.43	13.51	23	17218	4508	29552778
Dermatitis exfoliative generalised	28.57	13.51	19	17222	2897	29554389
Nasal discomfort	28.52	13.51	14	17227	1198	29556088
Product dispensing error	27.61	13.51	24	17217	5456	29551830
Petit mal epilepsy	27.31	13.51	18	17223	2704	29554582
Minimum inhibitory concentration	25.99	13.51	6	17235	44	29557242
Blood thyroid stimulating hormone decreased	25.97	13.51	15	17226	1783	29555503
Parkinsonism	25.39	13.51	26	17215	7252	29550034
Product administration error	25.00	13.51	36	17205	14274	29543012
Post procedural haemorrhage	24.77	13.51	26	17215	7465	29549821
Neutropenia	24.75	13.51	146	17095	131565	29425721
Vertigo	24.55	13.51	45	17196	21816	29535470
Subileus	24.20	13.51	17	17224	2833	29554453
Toxic skin eruption	23.94	13.51	29	17212	9728	29547558
Altered state of consciousness	23.68	13.51	42	17199	19847	29537439
Soft tissue mass	23.32	13.51	10	17231	626	29556660
Diffuse large B-cell lymphoma recurrent	23.25	13.51	16	17225	2581	29554705
Melaena	23.02	13.51	54	17187	31122	29526164
Stool analysis abnormal	22.98	13.51	5	17236	27	29557259
Hyperlipasaemia	22.39	13.51	9	17232	478	29556808
Illusion	22.37	13.51	10	17231	692	29556594
Hypokalaemia	22.14	13.51	72	17169	50131	29507155
Purpura	21.94	13.51	27	17214	9205	29548081
Campylobacter gastroenteritis	21.79	13.51	10	17231	736	29556550
Febrile neutropenia	21.79	13.51	20	17221	112220	29445066
Incontinence	21.33	13.51	20	17221	5012	29552274
Dysuria	21.28	13.51	43	17198	22397	29534889
Dissociation	20.64	13.51	11	17230	1118	29556168
Hanging	20.49	13.51	6	17235	120	29557166
Capillary fragility	20.46	13.51	5	17236	48	29557238
Febrile bone marrow aplasia	19.94	13.51	23	17218	7328	29549958
Bradycardia	19.60	13.51	83	17158	65546	29491740
Normocytic anaemia	19.57	13.51	13	17228	1979	29555307
Hepatitis cholestatic	19.43	13.51	22	17219	6871	29550415
Steroid diabetes	18.92	13.51	12	17229	1689	29555597
Dizziness	18.91	13.51	181	17060	189503	29367783
Haemoglobinaemia	18.86	13.51	6	17235	160	29557126
Prostatomegaly	18.76	13.51	18	17223	4643	29552643
Hallucination	18.70	13.51	63	17178	44649	29512637
Vitamin B12 decreased	18.53	13.51	10	17231	1042	29556244
Hallucination, visual	18.25	13.51	32	17209	14983	29542303
Pelvic fracture	18.23	13.51	13	17228	2218	29555068
Hypernatraemia	18.20	13.51	22	17219	7364	29549922
Hypovolaemic shock	18.18	13.51	20	17221	6052	29551234
On and off phenomenon	17.54	13.51	12	17229	1916	29555370
Growth hormone deficiency	16.94	13.51	6	17235	224	29557062
Cardiac failure congestive	16.91	13.51	12	17229	76569	29480717
Anaemia	16.81	13.51	185	17056	200766	29356520
Tonic clonic movements	16.78	13.51	9	17232	926	29556360
Hepatitis	16.44	13.51	37	17204	20746	29536540
Angina pectoris	16.13	13.51	44	17197	27806	29529480
Hyponatraemia	16.08	13.51	80	17161	67553	29489733
Hyperkeratosis	15.83	13.51	14	17227	3255	29554031
Hyperkalaemia	15.59	13.51	74	17167	61318	29495968
Expired product administered	15.57	13.51	13	17228	2798	29554488
Presyncope	15.45	13.51	31	17210	16058	29541228
Death	15.27	13.51	127	17114	341957	29215329
Amaurosis fugax	15.19	13.51	7	17234	520	29556766
Cystitis interstitial	15.00	13.51	5	17236	155	29557131
Blood pressure decreased	14.74	13.51	59	17182	45418	29511868
Paramnesia	14.73	13.51	3	17238	11	29557275
Behaviour disorder	14.62	13.51	14	17227	3602	29553684
Ketonuria	14.55	13.51	7	17234	573	29556713
Hyperhidrosis	14.40	13.51	75	17166	64465	29492821
Dyspnoea at rest	14.06	13.51	13	17228	3201	29554085
Eczema	13.71	13.51	27	17214	13799	29543487
Pancreatitis acute	13.60	13.51	38	17203	24347	29532939

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	194.94	13.88	371	15261	448869	64034231
Confusional state	91.70	13.88	198	15434	260946	64222154
Drug interaction	87.94	13.88	238	15394	361845	64121255
Cholestasis	84.73	13.88	77	15555	44795	64438305
Orthostatic hypotension	83.97	13.88	78	15554	46660	64436440
Thrombocytopenia	78.87	13.88	170	15462	223631	64259469
Drug dispensed to wrong patient	77.20	13.88	18	15614	359	64482741
Antimicrobial susceptibility test resistant	76.80	13.88	17	15615	266	64482834
Syncope	76.47	13.88	137	15495	157498	64325602
Agranulocytosis	74.93	13.88	67	15565	38162	64444938
Hepatocellular injury	70.85	13.88	70	15562	45165	64437935
Fall	69.32	13.88	240	15392	416586	64066514
Hypotension	62.12	13.88	218	15414	380756	64102344
Urinary retention	57.24	13.88	65	15567	49136	64433964
Eosinophilia	56.09	13.88	57	15575	38019	64445081
Coma	55.66	13.88	86	15546	87529	64395571
Therapeutic response delayed	53.27	13.88	16	15616	866	64482234
Neutropenia	51.64	13.88	151	15481	239473	64243627
Wrong patient received product	48.96	13.88	22	15610	3740	64479360
Pemphigoid	47.73	13.88	33	15599	12953	64470147
Hallucination, visual	45.30	13.88	44	15588	27790	64455310
Staring	44.30	13.88	18	15614	2392	64480708
Wrong product administered	39.12	13.88	24	15608	7696	64475404
Disorganised speech	36.18	13.88	14	15618	1636	64481464
Hyperkalaemia	35.74	13.88	77	15555	101052	64382048
Cell death	35.34	13.88	18	15614	4036	64479064
Completed suicide	35.24	13.88	6	15626	224408	64258692
Pain	35.03	13.88	50	15582	553461	63929639
Daydreaming	33.49	13.88	11	15621	799	64482301
Altered state of consciousness	32.59	13.88	43	15589	37859	64445241
Minimum inhibitory concentration	31.74	13.88	6	15626	40	64483060
Petit mal epilepsy	31.68	13.88	18	15614	5014	64478086
Dermatitis exfoliative generalised	31.54	13.88	19	15613	5897	64477203
Brain stem haematoma	31.24	13.88	7	15625	116	64482984
Allergy to animal	30.99	13.88	11	15621	1010	64482090
Toxic skin eruption	30.47	13.88	30	15602	19254	64463846
Bradycardia	29.86	13.88	79	15553	118140	64364960
Parkinsonism	29.76	13.88	26	15606	14347	64468753
Melaena	29.12	13.88	49	15583	53499	64429601
Disorientation	28.93	13.88	50	15582	55778	64427322
Haematuria	28.55	13.88	52	15580	60419	64422681
Soft tissue mass	28.38	13.88	10	15622	899	64482201
Prostatomegaly	28.29	13.88	14	15618	2953	64480147
Toxicity to various agents	28.12	13.88	28	15604	363485	64119615
Perseveration	27.77	13.88	8	15624	374	64482726
Apraxia	27.49	13.88	13	15619	2482	64480618
Drug intolerance	27.45	13.88	6	15626	187986	64295114
Hepatitis cholestatic	27.23	13.88	23	15609	12132	64470968
Alopecia	26.97	13.88	4	15628	165686	64317414
Febrile bone marrow aplasia	26.67	13.88	22	15610	11233	64471867
Campylobacter gastroenteritis	26.38	13.88	10	15622	1106	64481994
Status epilepticus	25.83	13.88	29	15603	21634	64461466
Purpura	25.72	13.88	26	15606	17220	64465880
Headache	25.23	13.88	57	15575	529410	63953690
Rheumatoid arthritis	24.48	13.88	5	15627	164289	64318811
Prostate cancer	24.46	13.88	27	15605	19768	64463332
On and off phenomenon	24.36	13.88	12	15620	2507	64480593
Product dispensing error	24.29	13.88	21	15611	11429	64471671
Hypovolaemic shock	24.18	13.88	20	15612	10246	64472854
Hyponatraemia	24.17	13.88	85	15547	148254	64334846
Hallucination	24.10	13.88	54	15578	72734	64410366
Subileus	24.02	13.88	15	15617	4962	64478138
Tonic clonic movements	23.89	13.88	11	15621	1978	64481122
Steroid diabetes	23.71	13.88	12	15620	2654	64480446
Hyperlipasaemia	23.69	13.88	9	15623	1001	64482099
Blood thyroid stimulating hormone decreased	23.34	13.88	15	15617	5215	64477885
Nasal discomfort	23.33	13.88	14	15618	4314	64478786
Illusion	23.07	13.88	10	15622	1560	64481540
Behaviour disorder	22.94	13.88	14	15618	4448	64478652
Bicytopenia	22.92	13.88	13	15619	3609	64479491
Hepatitis	22.54	13.88	40	15592	45542	64437558
Infusion related reaction	22.54	13.88	6	15626	164461	64318639
Dehydration	21.75	13.88	107	15525	216656	64266444
Pancreatitis acute	21.70	13.88	38	15594	42817	64440283
Haemoglobinaemia	21.38	13.88	6	15626	255	64482845
Hanging	21.24	13.88	5	15627	104	64482996
Hypokalaemia	20.85	13.88	71	15561	121832	64361268
Product administration error	20.21	13.88	29	15603	27614	64455486
Swelling	19.87	13.88	7	15625	160211	64322889
Pneumonia aspiration	19.65	13.88	44	15588	59227	64423873
Growth hormone deficiency	19.62	13.88	6	15626	345	64482755
Dissociation	19.58	13.88	11	15621	3000	64480100
Incontinence	19.47	13.88	19	15613	12062	64471038
Normocytic anaemia	18.64	13.88	11	15621	3288	64479812
Treatment failure	18.60	13.88	3	15629	116813	64366287
Dysuria	18.39	13.88	35	15597	42022	64441078
Psychomotor hyperactivity	18.36	13.88	20	15612	14431	64468669
Amaurosis fugax	18.24	13.88	7	15625	800	64482300
Pulmonary interstitial emphysema syndrome	17.99	13.88	6	15626	457	64482643
Capillary fragility	17.97	13.88	5	15627	206	64482894
Hyperkeratosis	17.82	13.88	14	15618	6667	64476433
Nausea	17.62	13.88	115	15517	785685	63697415
Vertigo	17.57	13.88	42	15590	58969	64424131
Blood pressure decreased	17.27	13.88	53	15579	86146	64396954
Subdural haematoma	17.05	13.88	27	15605	28027	64455073
Dementia	16.99	13.88	23	15609	20743	64462357
Expired product administered	16.96	13.88	13	15619	5974	64477126
Gynaecomastia	16.90	13.88	13	15619	6003	64477097
Anaemia	16.58	13.88	152	15480	378528	64104572
Amyotrophy	16.55	13.88	6	15626	585	64482515
Disturbance in attention	16.52	13.88	33	15599	41041	64442059
Drug hypersensitivity	16.51	13.88	20	15612	237795	64245305
Gout	16.44	13.88	23	15609	21390	64461710
Presyncope	16.34	13.88	30	15602	35059	64448041
Dyspnoea at rest	16.32	13.88	13	15619	6316	64476784
Intraventricular haemorrhage	16.32	13.88	11	15621	4142	64478958
Therapeutic product effect decreased	16.20	13.88	4	15628	115347	64367753
Product storage error	16.17	13.88	18	15614	13300	64469800
Lichenoid keratosis	15.97	13.88	10	15622	3324	64479776
Cerebral haemorrhage	15.90	13.88	37	15595	51053	64432047
Hyperhidrosis	15.75	13.88	66	15566	124854	64358246
Oversensing	15.74	13.88	3	15629	21	64483079
Cardiovascular insufficiency	15.49	13.88	9	15623	2615	64480485
Pallor	15.41	13.88	31	15601	38750	64444350
Abdominal discomfort	15.31	13.88	13	15619	182309	64300791
Paramnesia	15.18	13.88	3	15629	26	64483074
Inferior vena cava dilatation	15.13	13.88	6	15626	748	64482352
Leukopenia	14.78	13.88	56	15576	101186	64381914
Lactic acidosis	14.45	13.88	40	15592	61370	64421730
Renal failure	14.34	13.88	84	15548	181604	64301496
Atrioventricular block	14.18	13.88	16	15616	11999	64471101
Atrioventricular block second degree	14.02	13.88	12	15620	6442	64476658
Cardio-respiratory arrest	14.01	13.88	54	15578	98339	64384761
Hypernatraemia	13.99	13.88	16	15616	12173	64470927

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G04CA01	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
ATC	G04CA51	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
FDA MoA	N0000000099	Adrenergic alpha-Antagonists
FDA EPC	N0000175553	alpha-Adrenergic Blocker
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D064804	Urological Agents
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Benign prostatic hyperplasia	indication	266569009
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Low blood pressure	contraindication	45007003
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Cataract surgery	contraindication	110473004
Prolonged QT interval	contraindication	111975006
Angina pectoris	contraindication	194828000
Micturition syncope	contraindication	234168001
Disease of liver	contraindication	235856003	DOID:409
Intraoperative floppy iris syndrome	contraindication	418801006
Congenital long QT syndrome	contraindication	442917000
Progressive Angina Pectoris	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.09	acidic
pKa2	7.22	Basic
pKa3	0.97	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	ANTAGONIST	Ki	8.09	CHEMBL	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	ANTAGONIST	Ki	8.44	CHEMBL	CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	ANTAGONIST	Ki	8.55	CHEMBL	CHEMBL
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	7.75	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.83	CHEMBL
Alpha-1D adrenergic receptor	GPCR		ADA1D_RAT		Ki	8.46	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN		Ki	7.64	CHEMBL

External reference:

ID	Source
4021396	VUID
N0000148814	NUI
D01692	KEGG_DRUG
81403-68-1	SECONDARY_CAS_RN
17300	RXNORM
C0051150	UMLSCUI
CHEBI:51141	CHEBI
CHEMBL709	ChEMBL_ID
DB00346	DRUGBANK_ID
CHEMBL1723	ChEMBL_ID
C047638	MESH_SUPPLEMENTAL_RECORD_UI
2092	PUBCHEM_CID
7109	IUPHAR_LIGAND_ID
5357	INN_ID
90347YTW5F	UNII
16517	MMSL
184661	MMSL
43057	MMSL
47077	MMSL
d04797	MMSL
005431	NDDF
005432	NDDF
4021396	VANDF
349912006	SNOMEDCT_US
395725004	SNOMEDCT_US
395954002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5000	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	24 sections
ALFUZOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-021	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	25 sections
Uroxatral	HUMAN PRESCRIPTION DRUG LABEL	1	16590-279	TABLET, EXTENDED RELEASE	10 mg	ORAL	NDA	11 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-155	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-155	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Alfuzosin Hydrochlorideextended release	HUMAN PRESCRIPTION DRUG LABEL	1	31722-302	TABLET	10 mg	ORAL	ANDA	24 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	33261-994	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	25 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43353-746	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin hydrochloride	Human Prescription Drug Label	1	43353-945	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	24 sections
Alfuzosin Hydrochloride	Human Prescription Drug Label	1	47335-956	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Uroxatral	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5046	TABLET, EXTENDED RELEASE	10 mg	ORAL	NDA	28 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6329	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	55648-738	TABLET	10 mg	ORAL	ANDA	25 sections
Alfuzosin Hydrochloride	Human Prescription Drug Label	1	57237-114	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Uroxatral	Human Prescription Drug Label	1	59212-200	TABLET, EXTENDED RELEASE	10 mg	ORAL	NDA	27 sections
ALFUZOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	61919-349	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	18 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2353	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2353	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2354	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2354	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-7907	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-7907	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-9155	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-9295	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	64679-738	TABLET	10 mg	ORAL	ANDA	24 sections
Alfuzosin Hydrochloride	Human Prescription Drug Label	1	65862-249	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochlorideextended release	HUMAN PRESCRIPTION DRUG LABEL	1	69097-844	TABLET	10 mg	ORAL	ANDA	25 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70934-306	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochlorideextended release	HUMAN PRESCRIPTION DRUG LABEL	1	70934-961	TABLET	10 mg	ORAL	ANDA	25 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	71335-1529	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections